Evaluation agreements allow a party to the deal to obtain rights to a technology or compound, subject to...
Evaluation agreements allow a party to the deal to obtain rights to a technology or compound, subject to a period of time to evaluate the quality, scope and applicability of the technology to its intended endpoint. Normally the technology is at an early stage and/or unproven and the partnering company wishes to assess the technology as part of the due diligence process in advance of signing a long term licensing agreement.
An Evaluation agreement is often tied in with an option agreement. Option and evaluation agreements are favoured by big pharma companies as they allow a company to access a number of new emerging technologies rather than just a few. Big Pharma companies tend to make most option and evaluation agreements annually.
To view an example of an evaluation agreement, please see the report below:
View also: Other technology type reports
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity